Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Pluristem Ltd.
ClinicalTrials.gov Identifier:
NCT01525667
First received: January 31, 2012
Last updated: February 5, 2015
Last verified: January 2015
History of Changes
  Purpose

Local administration of PLX-PAD single dose, intra-muscular injection for the regeneration of injured gluteal musculature after Total Hip Arthroplasty (THA).


Condition Intervention Phase
Total Hip Arthroplasty
Muscle Injury
 Biological: 150M PLX-PAD
Biological: 300M PLX-PAD
Biological: Placebo
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty

Further study details as provided by Pluristem Ltd.:

Primary Outcome Measures:
  • Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength. [ Time Frame: Day 0 to Week 26 ] [ Designated as safety issue: No ]
    Change from Visit 2 (Day 0) to Week 26 in the maximal voluntary isometric contraction (MVIC) moment of the injured side as measured by isometric dynamometry to assess Gluteus Medius force strength.


Secondary Outcome Measures:
  • Change From Day 0 to Week 26 in Muscle Volume. [ Time Frame: Day 0 to Week 26 ] [ Designated as safety issue: No ]
    Change from Visit 2 (Day 0) to Week 26 in Muscle Volume as Measured by MRI.

  • Change From Day 1 to Week 12 in Mean Fiber Diameter. [ Time Frame: Day 1 to Week 12 ] [ Designated as safety issue: No ]
    Change from Visit 3 (Day 1) to Week 12 in Mean Fiber Diameter as Measured by Muscle Biopsy.

  • Change From Day 0 to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift . [ Time Frame: Day 0 to Week 26 ] [ Designated as safety issue: No ]
    Change from Visit 2 (Day 0) to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift as Measured by Gait Analysis

  • Change From Day 0 to Week 26 in the Visual Analog Scale (VAS) Pain Score. [ Time Frame: Day 0 to Week 26 ] [ Designated as safety issue: No ]
    Visual Analog Scale (VAS) Pain Score ranges from 0 mm (no pain) to 100 mm (worse possible pain)
Enrollment: 20
Study Start Date: November 2012
Estimated Study Completion Date: July 2015
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 150M PLX-PAD
Single course, multiple IM injections
 Biological: 150M PLX-PAD
Single course, multiple IM injections
Experimental: 300M PLX-PAD
Single course, multiple IM injections
 Biological: 300M PLX-PAD
Single course, multiple IM injections
Placebo Comparator: Placebo
Single course, multiple IM injections
 Biological: Placebo
Single course, multiple IM injections

Detailed Description:

One of the main problems when performing THA via the standard transgluteal approach is the necessary injury of the gluteus medius muscle. The consecutive decrease of contractile muscle substance and the substitution by scar tissue leads to functional deficits of the pelvic-stabilizing musculature with an insufficiency limp in a large number of patients. In the long run the lack of musculature leads to a decrease in bone substance at the insertion sites of the gluteal muscles of the proximal femur. The present study has the aim of establishing a new therapy for iatrogenic gluteal muscle damage. The hypothesis of the present proposal is that intra-muscular (IM) injection of PLX-PAD into the iatrogenically injured gluteus medius muscle after THA results in an improved regeneration of the skeletal muscle tissue and consecutively in an improved functional outcome.

Subjects will be assigned to receive one of the two targeted doses of PLX-PAD or placebo. On the treatment day, after suturing the gluteus medius muscle PLX-PAD or placebo will be applied directly to the site of laceration.

Patients will be followed up for efficacy assessment up to week 26 and for safety assessment (Adverse events, vital signs, ECG, routinf lab and immunological testing) up to week 52 after THA. Patients will be phoned at week 104 in order to inquire about the occurence of new cancer.

  Eligibility
Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects between 50 to 75 years of age
  2. Scheduled THA
  3. ASA Score ≤ 3
  4. Signed written informed consent

Exclusion Criteria:

  1. Muscle diseases
  2. Severe neurological diseases
  3. Opioid long term medication
  4. Pain chronification > stadium II of Gerbershagen
  5. Immunosuppression due to illness or medication
  6. Ankylosing spondylitis
  7. History of ectopic bone formation of any localisation
  8. Exclusion criteria for MRI (pace maker, defibrillator, ferromagnetic intracerebral clips)
  9. Uncontrolled hypertension (defined as diastolic blood pressure > 100 mmHg or systolic blood pressure > 200 mmHg during screening)
  10. Life-threatening ventricular arrhythmia or unstable angina - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged
  11. ST segment elevation myocardial infarction and/or TIA/CVA within three (3) months prior to enrollment. Subjects with severe congestive heart failure symptoms (i.e. NYHA Stage IV)
  12. Subject has malignancy undergoing treatment including chemotherapy, radiotherapy or immunotherapy
  13. Body Mass Index (BMI) of 35 Kg/m2 or greater
  14. Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the cell production process
  15. Known HIV, syphilis at time of screening
  16. Known active Hepatitis B, or Hepatitis C infection at the time of screening
  17. Pregnant or breast-feeding women or women of childbearing potential not protected by an effective contraceptive method of birth control (defined as pearl index < 1)
  18. In the opinion of the investigator, the subject is unsuitable for cellular therapy
  19. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s)
  20. Subjects who are legally detained in an official institute
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01525667

Locations
Germany
Charité Universitätsmedizin Berlin
Berlin, Germany, 10117
Sponsors and Collaborators
Pluristem Ltd.
Investigators
Principal Investigator: Carsten Perka, MD Charité Universitätsmedizin Berlin, Dept. Of Orthopedic Surgery, Charitéplatz 1, 10117 Berlin, Germany
  More Information

No publications provided

Responsible Party: Pluristem Ltd.
ClinicalTrials.gov Identifier: NCT01525667     History of Changes
Other Study ID Numbers: PLX-PAD 1301-01
Study First Received: January 31, 2012
Results First Received: January 1, 2015
Last Updated: February 5, 2015
Health Authority: Germany: Paul-Ehrlich-Institut

Keywords provided by Pluristem Ltd.:
THA
Muscle injury

ClinicalTrials.gov processed this record on March 03, 2015